- Raised $7.9M funding round, Jul 2025
- Raised $5M funding round led by Infinity China, Mar 2024
- Raised $8M funding round, Apr 2022
About
NovaSight is medical device company with a mission to prevent vision impairments among pediatric patients using eye tracking based technology in novel diagnostic, therapeutic and preventive solutions, especially designed for the unique needs of children. NovaSight focuses on three major verticals: vision treatment, vision diagnostics and prevention and monitoring of visual health conditions. Available in the US and Italy, the CureSight™ is an FDA cleared and CE marked amblyopia treatment system, designed to replace the traditional eye patching. The treatment is carried out while the patient watches his favorite streamed content from the comfort of home. By tracking the gaze position of the dominant eye in real-time, the CureSight system blurs its center of vision, while keeping the rest of the image sharp - and providing the amblyopic eye with a normal, high contrast, image. This stimulates the brain to complete the blurred image from the amblyopic eye, improving its acuity and developing stereoacuity as the eyes learn to work together. In addition, the CureSight system is connected to a dedicated cloud platform which allows the physician to monitor treatment progress and compliance remotely. The EyeSwiftPRO tests are grouped into automated ‘protocols’ such as amblyopia monitoring, binocular vision, etc. with each protocol running the unitary tests that are of clinical relevance to the protocol. At the end of each protocol, a clear report which is easily understood by the operator and the patient is created. NovaSight is also in the process of developing TrackSight™, a software as a service (SaaS) solution for myopia prevention and visual health monitoring. TrackSight is designed for use by children on laptops and tablets for both educational and leisure purposes as well as adults at the workplace for objective eye fatigue and dry eye monitoring.
Funding history · 6 rounds · $38.9M total
Q&A
- What is NovaSight's primary focus?
- NovaSight is a medical device company dedicated to preventing vision impairments in pediatric patients through eye-tracking based diagnostic, therapeutic, and preventive solutions.
- What is CureSight™?
- CureSight™ is an FDA-cleared and CE-marked amblyopia treatment system from NovaSight, designed to replace traditional eye patching. It allows patients to watch streamed content while the system blurs the dominant eye's central vision, stimulating the amblyopic eye.
- What is NovaSight developing for myopia prevention?
- NovaSight is developing TrackSight™, a software as a service (SaaS) solution for myopia prevention and visual health monitoring. It is designed for use by children on laptops and tablets, and by adults for objective eye fatigue and dry eye monitoring.
- When was NovaSight founded?
- NovaSight was founded in February 2016.
- How many employees does NovaSight have?
- NovaSight has 11-50 employees.
- What was NovaSight's most recent funding round?
- In July 2025, NovaSight raised $7,910,000 from investors including Arbelon Holdings Ltd.
- Which investors participated in NovaSight's March 2024 funding round?
- In March 2024, NovaSight raised $5,000,000 from Infinity China.
- What is the total amount of funding NovaSight has raised to date?
- NovaSight has raised a total of $38,880,000.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nova-sight.com |
|---|---|
| linkedin.com/company/11101854 | |
| facebook.com/profile.php?id=61564025591075 | |
| YouTube | youtube.com/channel/UCH-mzhGrUbVVwfzNwhQuA-g |
| instagram.com/nova_sight2016/ |
Identifiers & details
| Founded | 2016-2 |
|---|---|
| Employees (exact) | 14 |
| Offices | United States |
Radar intelligence
Patents
| EPO | 11 |
|---|
Publications (Crossref)
| Works | 5 |
|---|
Web history (Wayback)
| Domain | nova-sight.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|